| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9060939 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US7947739 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8022106 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8273795 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8487005 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8791160 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8957113 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
| US8809394 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(1 year, 5 months from now) | |
Lysteda is owned by Amring Pharms.
Lysteda contains Tranexamic Acid.
Lysteda has a total of 8 drug patents out of which 0 drug patents have expired.
Lysteda was authorised for market use on 13 November, 2009.
Lysteda is available in tablet;oral dosage forms.
Lysteda can be used as treatment of cyclic heavy menstrual bleeding.
The generics of Lysteda are possible to be released after 04 March, 2025.
Drugs and Companies using TRANEXAMIC ACID ingredient
Market Authorisation Date: 13 November, 2009
Treatment: Treatment of cyclic heavy menstrual bleeding
Dosage: TABLET;ORAL
LYSTEDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic